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Background: The global trend of increased life expectancy and increased prevalence of chronic and degenerative
diseases will impact on health systems. To identify effective intervention and prevention strategies, greater
understanding of the risk factors for and cumulative effects of chronic disease processes and their effects on
function and quality of life is needed.
The Busselton Healthy Ageing Study aims to enhance understanding of ageing by relating the clustering and
interactions of common chronic conditions in adults to function. Longitudinal (3–5 yearly) follow-up is planned.
Methods/design: Phase I (recruitment) is a cross-sectional community-based prospective cohort study involving up to
4,000 ‘Baby Boomers’ (born from 1946 to 1964) living in the Busselton Shire, Western Australia. The study protocol
involves a detailed, self-administered health and risk factor questionnaire and a range of physical assessments including
body composition and bone density measurements, cardiovascular profiling (blood pressure, ECG and brachial pulse
wave velocity), retinal photography, tonometry, auto-refraction, spirometry and bronchodilator responsiveness, skin
allergy prick tests, sleep apnoea screening, tympanometry and audiometry, grip strength, mobility, balance and leg
extensor strength. Cognitive function and reserve, semantic memory, and pre-morbid intelligence are assessed.
Participants provide a fasting blood sample for assessment of lipids, blood glucose, C-reactive protein and renal and
liver function, and RNA, DNA and serum are stored. Clinically relevant results are provided to all participants. The
prevalence of risk factors, symptoms and diagnosed illness will be calculated and the burden of illness will be
estimated based on the observed relationships and clustering of symptoms and illness within individuals. Risk factors
for combinations of illness will be compared with those for single illnesses and the relation of combinations of illness
and symptoms to cognitive and physical function will be estimated.
Discussion: This study will enable a thorough characterization of multiple disease processes and their risk factors within a
community-based sample of individuals to determine their singular, interactive and cumulative effects on ageing. The
project will provide novel cross-sectional data and establish a cohort that will be used for longitudinal analyses of the
genetic, lifestyle and environmental factors that determine whether an individual ages well or with impairment.
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Substantial rises in the prevalence of many chronic dis-
eases and degenerative conditions such as cardiovascular
disease, cancer, diabetes, depression, dementia, asthma,
chronic obstructive pulmonary disease (COPD), arthritis,
osteoporosis, sarcopaenia, hearing loss and vision disor-
ders have occurred in Australia and other developed coun-
tries over the last 3 decades [1]. In 2003, approximately
20% of Australians (~4 million people) reported having a
chronic condition leading to disability [1] and this per-
centage is likely to rise substantially if current trends of in-
creased rates of obesity and decreasing physical activity in
the general population continue. In Australia, like many
other nations, the mean age of the population has been in-
creasing. By 2050, it is estimated that almost one quarter
of the population will be aged 65 years or older [2].
Australian surveys conducted in 2004 indicate that ap-
proximately 30% of adults aged between 45 and 64 years
had 5 or more long-term co-morbidities, a percentage that
increased to 55% for those aged 65–85 years, and to 65%
for those over 85 years [3]. Concurrent chronic and de-
generative diseases are associated with significant long-
term morbidity and mortality, and are a major public
health challenge for Australia and the rest of the world [4].
For example, the health burden from back pain with de-
pression is substantially greater than back pain without
depression [5]. An ageing population that has a dispropor-
tionate number of individuals with one or more co-
morbidities will place significant demands on the health
system, the first effects of which will likely be seen in the
near future as the current baby-boomer generation (born
1946–1964) reaches ages associated with the highest rates
of morbidity. In the context of health systems that are
already under pressure, there is an urgent need to assess
the global effects of concurrent illnesses to identify the
most effective strategies for intervention and prevention.
In recent years, there have been efforts to define what
constitutes ‘healthy ageing’ [6]. Studies have assessed
measurable constructs that contribute to overall quality
of life and include the absence of disability and chronic
disease, the maintenance of optimal physical and cogni-
tive function and the importance of psychological health
and social connectedness. The search to define a ‘healthy
ageing’ phenotype [6] has placed an emphasis on an in-
tegrated multidisciplinary approach with recommenda-
tions that research efforts focus on a number of areas
including: physical activity, fitness and sleep, effects of
well-being or psychological health on biological mecha-
nisms of disease and resilience, prevention strategies
through combined lifestyle and pharmacological inter-
ventions, and defining reversible changes prior to disease
and disability through the identification of new bio-
markers [6]. Underpinning these recommendations, is a
growing recognition that a number of age-related diseaseprocesses are likely to arise from common pathways and
perhaps provide opportunities to maximise the benefits of
intervention and prevention. For instance, age-related hor-
monal changes or lifestyle factors such as obesity, malnu-
trition and lack of physical activity may exacerbate
inflammation and cellular damage leading to metabolic
dysregulation. Metabolic dysfunction is a common process
that may underlie a range of conditions and the progres-
sion to chronic disease. Examples include the progression
of insulin resistance to diabetes, atherogenesis and
dyslipidemia to cardiovascular disease, neurocognitive de-
cline to dementia, and osteopenia to osteoporosis [6].
By understanding the trajectories of chronic diseases
and the nature of the complex relationships amongst
them, insights can be gained into the impact of combina-
tions of illnesses and symptoms on function and quality of
life. This will inform the development of strategies that
focus on the maintenance of function to better ensure en-
gaged, productive and healthy ageing of individuals. It is
increasingly clear that chronic disease research and, by ex-
tension, management of the burden and risk of future
chronic disease, must be approached holistically rather
than on a disease-by-disease basis.
There have been a number of recent cohort studies
which have examined the burden of disease in ageing popu-
lations. Some of these have necessarily focused on specific
diseases [7-9] and some have been confined to a particular
sex or to older subjects [10,11] or have been limited (due to
very large samples) to questionnaire-derived data [12]. The
Busselton Healthy Ageing Study (BHAS) will use a multi-
disciplinary approach to understand the impact of illness
on healthy ageing. The strategy is to study a moderately-
large cohort intensively, by collecting a wide range of mea-
sures of physical function, cognition, well-being, quality of
life and medical history as well as biological samples in
order to discover the important relationships between dis-
ease processes and symptoms within individuals. The study
will establish a cohort for investigations into the develop-
ment of morbidity and reduced function and quality of life
into old age. The generation born from 1946 to 1964 (baby
boomers) offers an ideal sample to study the factors associ-
ated with ageing. The 20-year interval between the youn-
gest and oldest members in this cohort provides an
opportunity to investigate both early and established disease
processes and trajectories associated with ageing and to
identify early biomarkers of chronic or degenerative condi-
tions. The BHAS will also establish a platform from which
early intervention strategies can be implemented and evalu-
ated. Phase 1 of the study is designed around the following
hypotheses, that:
1. multiple physical and cognitive illnesses and their
risk factors contribute to the total burden of disease
and that there is considerable variation in the
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individuals);
2. the overall burden of illness in an individual is
determined not just by specific illnesses but also by the
combination of illnesses and their aggregate effects;
3. quality of life and physical and cognitive function are
partly determined by various factors
(socio-demographic factors and illness risk factors)
that contribute to the total burden of illness and;
4. the burden of illness, together with measures of
physical and cognitive function and quality of life,
are associated with health care utilization,
employment and occupation, residential setting and
community participation.
Study design
The Shire of Busselton is a coastal community in the
South-West of Western Australia with a relatively stable
population of predominantly European descent. The Shire
has been the site of repeated cross-sectional surveys of
adults from 1966 to 2009, with participation rates ranging
from 64 to 91% [13]. Health surveys have previously fo-
cused on specific systems or diseases: respiratory [14,15];
cardiovascular [16-18]; gastrointestinal [19]; endocrine
[20]; iron metabolism [21,22]; cancer mortality [23]; the
“metabolic syndrome” [24]; dementia and diabetes [25]
and genetic epidemiology [13,26-28].
Phase I of the BHAS is a cross-sectional study of
community-dwelling adults, born 1946 to 1964 and ran-
domly selected from the Shire electoral roll. Longitudinal
follow-up of the same cohort is planned every 3–5 years
(Phase II). The study has received ethics approval from the
University of Western Australia Human Research Ethics
Committee (Number RA/4/1/2203) and participant re-
cruitment commenced in May 2010.
Aims
The general aim of the BHAS is to identify the cumula-
tive effects of disparate illnesses that constitute the bur-
den of disease that impacts on healthy ageing, starting
with a detailed assessment of physical function, cognitive
performance and quality of life in baby boomers’.
The specific aims of Phase 1 of the study are to:
1. Determine:
a) Prevalence of chronic physical and mental illness
b) Prevalence of potential multiple-domain risk
factors
c) Quality of life and health burden, in 4000 baby
boomers from a community-dwelling population
sample.
2. Determine the clustering within individuals of:
a) physical and mental illnesses
b) potential risk factors.3. Determine clustering, across individuals, of:
a) physical and mental illnesses
b) risk factors
c) burden of illness, based on age, sex, and socio-
economic factors.
4. Examine associations between illness clusters and
risk factor clusters.
5. Collect and store serum, DNA and RNA from blood
samples for future studies of genetic risk factors and
gene-environment interactions and for the
identification of biomarkers associated with ageing
and disease.
6. Provide a baseline for follow-up assessments to
enable analysis of changes in risk factors and
outcomes with a view to determination of factors
that impact on healthy ageing, healthcare utilization,
employment and occupation, residential setting, and
community participation.
Methods/design
Study sample and recruitment process
The Busselton Shire comprises about 1.25% of the Western
Australian population (25,355 people according to the 2006
Australian Census) and a total of 6,690 adults born from
1946 to 1964 are registered on the 2010 electoral roll in the
region, with 48.4% being male and an average of 352 indi-
viduals per year of birth group. All non-institutionalised
baby boomers who currently live in the Shire and listed on
the electoral roll are eligible to participate. Order of invita-
tion to participate is randomized, with recruitment efforts
focused upon sequential 10% sample draws. Contact with
participants is via a letter of introduction, followed by a
phone call to invite them to attend the testing centre for a
four hour appointment. Addresses are obtained from the
electoral roll and phone numbers are obtained from local
residential and business directories.
Phase I of the BHAS commenced mid-2010 and will
run until 2013. Based on current recruitment progress
and participation rates, it is anticipated that approxi-
mately 4,000 participants will be recruited and tested
(59% of those listed on the electoral roll).
Questionnaire data collection
All participants who attend the testing centre complete
a self-administered questionnaire that collects informa-
tion on the following:
Demographics
Age, sex, marital status, ancestry/ethnicity, highest edu-
cation level obtained and age at completion, current and
previous occupational history (including years spent in
longest occupation and exposure to dust), household in-
come, dwelling type, years lived at current dwelling and
occupancy status.
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Information on smoking history and exposure to environ-
mental tobacco smoke at home or work is recorded along
with alcohol consumption, dietary intake of meat, fruit,
vegetable, dairy and cereals and also foods avoided or
never eaten.
Physical activity and sedentary behaviour is assessed
using the short form of the International Physical Activity
Questionnaire, IPAQ [29]. The average number of hours
of sleep obtained over a typical 24 hour period, exposure
to occupational noise, and information on household floor
coverings and pet ownership is also collected.
Information technology exposure including mobile
phone, television, computer and internet usage is
assessed using the Young People’s Activity Question-
naire [30]. Attitudes to information technology are
assessed with the computer confidence subscale of the
Computer Attitudes Scale [31] that has independently
verified factor constructs [32].
Information on social inclusion and community values
is collected using nine items from the Social Capital Ques-
tionnaire (SCQ) [33], which encompasses constructs of
“feelings of trust and safety”, “neighbourhood connections”
and “proactivity in the social context”. Information on life
values, including self-reported importance of financial se-
curity, social and job status and personal relationships is
also collected.
Medical history
Current use of prescribed and non-prescribed medica-
tion and supplements are collected along with medical
history including age at doctor-diagnosis of the following
diseases and conditions:
 Cardiovascular conditions including: angina,
claudication, high blood pressure, high cholesterol,
implant of cardiac pacemaker, heart attack, transient
ischaemic attack, stroke,
 Endocrine conditions including: diabetes (Type I, II
or gestational), osteoporosis, kidney disease and
thyroid disease.
 Neurological conditions including: Alzheimer’s
disease, vascular dementia (multi-infarct dementia),
Parkinson’s disease, attention deficit (hyperactivity)
disorder, anxiety disorder including post traumatic
stress disorder, depression, bipolar disorder,
schizophrenia and epilepsy.
 Allergies and respiratory conditions including:
asthma or bronchial asthma, chronic obstructive
pulmonary disease, pneumonia, pleurisy, bronchitis,
sinusitis, hay fever or allergic rhinitis, food allergies
and anaphylaxis.
 Sleep disorders including: narcolepsy and obstructive
sleep apnoea. Gastrointestinal disorders including: stomach
(gastric) or duodenal ulcer, colon cancer, colonic
polyps, coeliac disease, gastro-oesophageal reflux
disease, hiatus hernia, Crohn’s disease, ulcerative
colitis (or proctitis), irritable bowel syndrome,
diverticular disease, gallstones and haemorrhoids.
 Other medical conditions including: cancer, chronic
ear infection, Ménière’s disease, macular
degeneration, glaucoma, cataract, injury or trauma
resulting in loss of vision, trauma to the head or
neck, migraine, headache, anaemia, arthritis,
cirrhosis of the liver, fatty liver, poliomyelitis and
urinary tract infection.
Information on the age of each participant’s biological
parents and siblings and cause of death (if deceased) is col-
lected along with family history of common medical condi-
tions including asthma, diabetes, hay fever, hearing loss,
high blood pressure, myocardial infarction, stroke, glau-
coma, macular degeneration and cancer. Consent is also
requested from participants to allow their coded study in-
formation to be linked to information routinely collected
by the Western Australian Department of Health, such as
hospital admissions, and other government departments
responsible for births, deaths and marriage records.
Physical symptoms
The questionnaire also collects information on a range
of current symptoms including the following:
 Spinal pain: Location, frequency, duration and
intensity of back pain is assessed based on the
Nordic Questionnaire which has demonstrated
reliability and validity [34], with modifications based
on subsequent research [35-37]. The impact of low
back pain on daily activity and physical activity as
well as health care use, medications taken, health
professionals visited and work/study days lost [38].
Beliefs about spinal pain are assessed with the Fear
Avoidance Beliefs Questionnaire [39], the
catastrophising subscale of the Coping Strategies
Questionnaire [40] and the Back Pain Beliefs
questionnaire [41]. Disability related to low back
pain is assessed with the Oswestry Disability Index
[42] and items from the Örebro Musculoskeletal
Pain Questionnaire [43].
 Respiratory symptoms: Incidence and frequency of
wheeze, breathlessness (at rest or on exertion), chest
tightness and cough and phlegm are collected using
standardized questions from the British Medical
Council Respiratory questionnaire [44].
 Sleep symptoms: Information on day-time
somnolence, snoring frequency, witnessed apnoeas,
frequency of unrefreshed sleep and waking tired or
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Epworth Sleepiness Scale [45] and the Berlin
Questionnaire [46].
 Hearing impairment: Frequency and effect of
hearing loss/impairment, tinnitus, hyperacusis
(intolerance to sound), imbalance and dizziness on
daily life and activities are collected.
 Mental health: Current level of depression, anxiety
and stress are assessed using the Depression,
Anxiety and Stress Scale (DASS21) [47] and
depressive severity is measured using the Patient
Health Questionnaire - 9 (PHQ-9) [48]. Information
on current treatment for depression including
medication, exercise or psychological counselling is
also collected.
Quality of life
Self-reported health rating, long standing disability or ill-
ness and the impact of physical and mental function on
daily activities is assessed using the Short Form SF-12®
Health Survey [49].
Study centre data collection
Participants spend up to four hours at the study centre
in Busselton where they provide a fasting blood sample
and undergo comprehensive physical and cognitive as-
sessments. The order of tests is specifically scheduled to
minimise possible confounding interactions (Table 1).
Blood sample
A fasting venous blood sample is collected from the cu-
bital fossa in evacuated clot, fluoride/oxalate, ethyl-
enediaminetetraacetic acid (EDTA) and gel serum
separator tubes (SST) (BD Biosciences, Australia).
Whole blood is also collected in PAXgene® blood tubes
for preservation of RNA for later gene expression stud-
ies. A range of haematological and biochemistry tests
(Table 2) is conducted on fresh samples by PathWest
laboratories (Busselton and QEII Medical Centre,
Nedlands, Western Australia). Serum, plasma and buffy
coat fractions are processed and separated onsite for
biospecimen banking. DNA and RNA will be extracted
and stored by the Western Australian DNA Bank.
Anthropometry and body composition
Standing height, neck, waist and hip girth, and weight
are measured with the participant lightly-clothed and
shoeless using standard anthropometric techniques.
Upper airway (oropharaynx) anatomy is visually exam-
ined and Mallampati and pharyngeal grading is scored
[50]. Body mass index (BMI) is calculated as well as
waist to hip ratio (WHR). Dual energy X-ray absorpti-
ometry (DEXA) scans (AP spine and dual femur) are
undertaken to assess bone mineral density (BMD) usinga GE Lunar Prodigy Pro densitometer and enCORE Ver-
sion 13 (GE Health) software. Bone mineral density is
measured in grams per centimetre squared (g/cm2) and
young adult T-scores and age-matched z-scores are de-
rived using the combined Geelong/Lunar reference data-
base (GE Health). Full body densitometry scans are
performed to measure regional body fat distribution,
total lean tissue, whole body bone mineral content
(BMC) and fat mass. The percentage of total body fat,
android fat, gynoid fat, and the android/gynoid ratio are
calculated. All body composition scans collected can be
manipulated to define custom regions of interest for spe-
cific fat compartmentalisation or distribution analyses.
Cardiovascular
A resting 12-lead electrocardiogram (ECG) and rhythm
strip is recorded digitally using a CardioPerfect PC-
based resting ECG (Welch Allyn). Blood pressure in all
four limbs is measured with the participant supine, after
5 minutes of rest. Pulse, systolic, diastolic and mean ar-
terial blood pressures are measured using a vascular pro-
filer (Omron VP1000). Estimations of arterial occlusion
and distensibility are derived from the ankle brachial
index and brachial-ankle pulse wave velocity measure-
ments. Vascular profiling is not performed on partici-
pants with recent thrombosis or lymphadenectomy or
other conditions in which application and inflation of
the cuffs is likely to cause discomfort or exacerbations.
Respiratory and allergy
Forced expired volume in one second (FEV1) and forced
vital capacity (FVC), before and 15 minutes after salbuta-
mol (200 mcg) delivered via a metered-dose inhaler and
spacer, are measured using an EasyoneTM spirometer and
compared with predicted values [51]. Participants are
asked to withhold short-acting inhaled bronchodilators for
at least eight hours prior to spirometry and long-acting
bronchodilators for 48 hours where possible. Spirometry
is rescheduled if the participant has undergone eye surgery
or has had a detached retina, heart problems or abdominal
or chest surgery in the last 3 months, or has had influenza
or a chest infection within the last 2 weeks. Swabs of the
posterior wall of the oropharynx are collected and stored
for later bacterial identification by DNA sequencing. DNA
will be extracted from the swabs and submitted to PCR
amplification of the V3-V5 variable region of bacterial 16S
rRNA. Skin prick tests to common aero-allergens (Grass
Mix #7, Rye Grass Pollen, dust mites: Dermatophagoides
pteronyssinus and Dermatophagoides farinae, Cat-Pelt,
Dog Hair Dander, Mould Mix #10, Alternaria tenius
and Aspergillus fumigatus (Stallergenes, France)) is
performed on the anterior forearm. Wheals 3 mm, or
greater, in diameter measured at 15 minutes post-
application and pricking are scored as positive reactions.
Table 1 Schedule of testing in the Busselton healthy ageing study
Test Components
1 Specimen collection Fasting blood sample and oropharynx swab
2 Anthropometry Height*, weight*, neck, hips, waist, Mallampati score and pharyngeal grade
3 Participant break Refreshment break with food provided
4 Cognition MMSE, AusNART, category and letter fluency test, CDR battery
5 Body composition Anterior- posterior spine, dual femur and total body densitometry scans*
6 Eyes & vision Tonometry, keratometry, autorefraction, retinal photography
7 Cardiovascular 12 Lead ECG*, vascular profiling (blood pressures, pulse wave velocity)
8 Ears & hearing Otoscopy, tympanometry, audiometry*
9 Respiratory Baseline spirometry*
10 Allergy Forearm skin prick test*
11 Physical tests Force plate jump, balance, timed up and go, chair rises, grip strength
12 Bronchodilator response Spirometry >15 minutes post salbutamol*
13 Sleep monitor instruction Sleep monitor instruction and overnight sleep study performed in-home*
*Results provided to participant.
Abbreviations: AusNART Australian National Adult Reading Test; CDR Cognitive Drug Research; ECG Electrocardiogram; MMSE Mini Mental State Examination.
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used. Participants are asked to refrain from taking antihista-
mine medications for at least 1 week prior to allergy testing,
where possible.Ears and hearing
Otoscopic examination of the external auditory canal
is performed using a Mini 3000 otoscope (Heine,
Germany) and visibility of the tympanic membrane,
outer ear structures, obstructions and discharges are
noted. Ear canal volume, middle ear pressure and
compliance of the tympanic membrane are measured
using an Otowave tympanometer (Amplivox Ltd,
United Kingdom). Tympanometry is rescheduled if a
participant has undergone ear surgery, perilymph
fistula or barotrauma within the previous three months.
Pure tone air and bone conduction thresholds are
determined using automated audiometry with AMTAS
software (AMTAS, Audiometry Incorporated, USA) con-
trolling a Conera audiometer (GNOtometrics, Copenhagen,
Denmark), with Sennheiser HDA 200 (Wennesbostel,
Germany) headphones, on a NOAH platform (Hear-
ing Instrument Manufacturers’ Software Association,
Copenhagen, Denmark) and conducted in a sound-
proof booth (Acoustic Designs, Australia) [52]. The
participants are first instructed through the head-
phones. The testing protocol is in accordance with
Hughson-Westlake methods. Participants are asked to
respond with “Yes” or “No” after the presentation of
every stimulus using a touch screen. Air conduction
thresholds are recorded at 250, 500, 1000, 2000, 4000
and 8000 Hz, and bone conduction thresholds at 500,
1000, 2000, and 4000 Hz.Eyes and vision
Intraocular pressure (IOP) is measured using a rebound
tonometer (Icare, USA) and the average of 6 measure-
ments for each eye is recorded in millimetres of mercury
(mmHg). Keratometric and autorefraction measurements
are taken using a handheld Auto Ref/Keratometer ARK-30
(Nidek, Japan) to assess refractive errors and to determine
corneal curvature radius (corneal refractive power). A
high-resolution digital retinal camera (Canon CR-1, Japan)
is used to capture two images, one centred on the optic
disc and the other centred on the macula. These images
are assessed for pathological features of age-related macu-
lar degeneration and glaucoma. All eye assessments are
conducted after dilation of the pupil using a mydriatic so-
lution (tropacamide 1%) administered 15 to 20 minutes
prior to testing.Physical function, neuromuscular strength and power
Dynamic muscle power and strength of the leg extensors
are assessed using a Ballistic Measurement System (Fitness
Technology, Australia) which incorporates a force plate
(400 series, Fitness Technology, Australia) for measure-
ment of ground reaction force [53]. Participants are asked
to perform a countermovement vertical jump for max-
imum height from the force plate and the highest power
output and force reproducible to within 5% from up to 8
trials is recorded. A number of parameters are measured
or derived including peak and average force, impulse, peak
and average power output, peak velocity, maximum rate
of force development, and jump height. Participants with
current back, hip, knee or ankle pain may withdraw from
the jump test at their discretion. Mobility is measured
using the timed up and go (TUG) test [54]. Lower-body
Table 2 Haematology, biochemistry and biological
specimen banking in the Busselton healthy ageing study
Haematology* Analysate
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General chemistry (plasma) C-reactive protein
Glucose
Insulin
General chemistry (whole blood) Glycated haemoglobin
Bio-specimen banking#
Buffy coats DNA extraction and analyses
PAXgene® Blood tubes RNA extraction and
expression analyses
Table 2 Haematology, biochemistry and biological
specimen banking in the Busselton healthy ageing study
(Continued)
Oropharynx swabs Bacterial DNA extraction
and analyses
Serum Aliquots for biochemistry
Plasma Aliquots for biochemistry
*Results provided to participant; # Specimens stored at −80°C.
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Times Sit to Stand Test (5TSTS) [55]. The test involves re-
cording the time taken for the participant to perform 5 suc-
cessive chair rises from a seated position with arms folded
across the chest. Hand grip-strength is measured in kilo-
grams using a hand dynamometer (Model 78010, Lafayette
Instrument, USA) with the results of 3 trials (within 5%)
recorded for each hand.
Balance and risk of falling
Static balance is assessed using a force plate (400 Series,
Fitness Technology, Australia) with vertical forces analysed
to determine the centre of pressure on the plate. A modi-
fied clinical test of sensory interaction on balance involves
the participant standing stationary for 30 seconds on the
force plate during four conditions; a) eyes open and b) eyes
closed, while standing on a stable surface, and c) eyes open
and d) eyes closed, while standing on an unstable surface
[56]. During these trials movement of the centre of pres-
sure and postural sway is recorded using Inner Balance
software (Innervations, Australia).
Cognition
Cognitive testing focuses on episodic memory assess-
ment, as well as tests of attention and executive func-
tion. Memory and attention is assessed using the
Cognitive Drug Research (CDR) [57] computerised as-
sessment system (United BioSource Corporation, UK).
This has been used extensively in clinical and longitu-
dinal studies, including the dementias, over the last
20 years, has been shown to be sensitive to subtle cogni-
tive changes, and has the largest normative database of
its kind [57]. The battery consists of several key tasks in-
cluding: immediate and delayed word recall and recogni-
tion, simple and choice reaction time, digit vigilance,
spatial and numeric working memory and delayed pic-
ture recognition. Participants also complete measures of
retrieval ability and executive functioning using the
phonemic (letters C, F, L) and semantic (category - ani-
mal) fluency test with trials conducted over 1 minute
[58]. Pre-morbid intelligence is estimated from scores on
the Australian National Adult Reading Test (AusNART)
[59] and used as an index of cognitive reserve. Partici-
pants also complete the Mini Mental State Examination
(MMSE) [60].
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Sleep apnoea screening devices are offered to participants
to use over one night at home. Sleep studies are under-
taken using dual channel (oximetry & nasal pressure)
ApneaLink™ devices (Resmed, Australia). Participants are
instructed on how to fit and operate the units and are also
provided with an instruction card and tape for cannula at-
tachment to the cheek. The monitors are returned to the
study centre the following day. Data are downloaded and
automatically analysed using ApneaLink software version
8.00. Scores of respiratory disturbances including snoring
events, apnoea hypopnea index and oxygen desaturation
and duration are recorded. Each participant is provided
with a score sheet and explanatory guide to indicate the
level of sleep–disordered breathing based upon risk index
scores at different cut-offs (normal <5, mild 6–20, moder-
ate 21–30 and severe >30). Participants who receive
current CPAP or mandibular advancement splint therapy
for sleep apnoea are excluded from the sleep apnoea
screening study.
Information provided to participants
Following completion of the testing protocol and return of
the questionnaire, participants receive an explanatory
guide and copy of the following test results: height, weight,
waist measurement, haematology and biochemistry, lung
function, skin test responses, cardiovascular profile (blood
pressure and ankle-brachial index), bone density, audiom-
etry and sleep apnoea screening test. All results from the
physical tests are discussed with the senior scientist onsite
and blood tests are posted to participants after being
reviewed by the study chief clinical investigator. Partici-
pants are urged to provide a copy of their results to their
general practitioner where indicated.
Data capture and management
Hard copies of questionnaires are converted to electronic
portable document file (PDF) format and data are
extracted and verified on-site using Cardiff TELEform
software (Verity Inc. Sunnyvale, CA). These data, along
with automatic data capture capabilities from most of the
devices being used are stored with the existing Busselton
Health Study collection which is managed by the School
of Population Health, University of Western Australia.
Quality control
Each study participant is taken through the testing proto-
col by a single research assistant. Therefore, all research
assistants are trained in all aspects of testing. Training is
conducted on-site and, where necessary, within the labora-
tories of each of the participating investigators under the
supervision of experienced laboratory staff, until the re-
quired standard of testing and competency is achieved.
Raw data are reviewed weekly in-house or within thelaboratories of investigators to ensure that standards are
maintained, with regular feedback to research assistants
and further instruction or adjustments provided where ne-
cessary. Complex interpretation and review of results from
retinal photographs and bone density scans are under-
taken off-site by experienced, specialised staff within the
participating laboratories. All equipment is maintained,
serviced and calibrated according to manufacturer’s speci-
fications and schedules.
Data analysis and statistical power
It is expected that most analyses will be based on adequate
data for about 4,000 people (with about equal numbers of
men and women and with relatively uniform numbers
across the year-of-birth groups). The statistical approaches
used to investigate the aims of the BHAS Phase 1 are:
Estimation of the prevalence of multiple chronic disease
processes
Questionnaire results and the results of physical and
cognitive testing will be recorded to calculate the preva-
lence of diagnosed illness, medication use, current symp-
toms, current cognitive and physical functional status,
quality of life and risk factors for disease. Logistic regres-
sion and linear regression methods will be used to com-
pare and analyse trends in prevalence and mean levels
and to investigate risk factors for illnesses. With 4,000
participants, there will be an average of 105 people in
each sex-year-of-birth group and this will allow the
prevalence (as a proportion) in each group to be esti-
mated with standard error of 0.03 to 0.04 (for prevalence
proportions ranging from 0.1 to 0.25) and much more
accurately when groups are aggregated or estimates are
based on fitted logistic models. This sample size will
provide over 85% power to detect differences as small as
0.05 in prevalence proportions (ranging from 0.1 to
0.25) between men and women or between groups de-
fined by risk factors and symptoms with prevalence
around 25%.
Determination of the aggregation, clustering and
distribution of illnesses (burden of illness)
Burden of illness will be based on the number and spe-
cific types and combinations of illnesses. Frequency
(contingency) tables and logistic regression methods will
be used to investigate relationships between illnesses
and how these vary across socio-demographic groups.
Generalised linear regression methods will be used to
identify risk factors for number and combinations of ill-
nesses (and symptoms) and compare these with the
standard risk factors for individual illnesses. Cluster ana-
lysis methods (e.g. k-means cluster and latent class ana-
lysis) will be used to identify clusters of people who are
homogeneous with respect to risk factors and symptoms
James et al. BMC Public Health 2013, 13:936 Page 9 of 12
http://www.biomedcentral.com/1471-2458/13/936and then contingency table methods will be used to ex-
plore the relationships between the clusters and specific
illnesses and combinations of illnesses.
Physical and cognitive function and quality of life and
relationship to the burden of illness and risk factors
for illnesses
Generalised linear regression models using the SF-12®
Health Survey quality-of-life score and measures of cogni-
tive function (memory, attention, executive function, cat-
egory and letter fluency and reading test) and physical
function (static balance, chair-rise, timed up and go, muscle
strength and power) as outcomes will be used to examine
the relationship of illnesses (and burden of illness), symp-
toms and risk factor variables with these outcomes.
Future longitudinal analyses
Changes from baseline to four-year follow-up in risk fac-
tors, socio-demographic factors and living arrangements,
and outcomes (physical function, cognitive function and
quality of life) will be measured and relationships be-
tween them investigated using standard longitudinal data
regression methods (such a generalised mixed models
and GEE estimation). The focus of these analyses will be
to understand the patterns and processes of healthy (and
unhealthy) ageing and the identification of factors that
are associated with healthy ageing.
Discussion
The impact and costs of failing health are predicted to
be a significant burden on health systems and society
over the coming years [61]. For example, preventable,
non-communicable chronic diseases are now responsible
for over 70% of the illness and injury experienced by the
Australian population, projected to rise to 80% by 2020.
Internationally, all levels of Government are searching
for ways to manage this financial and social imperative.
Preventive medicine strategies, management of illness,
health planning and optimal use of the health system
rely on relevant, current and integrated data on the
prevalence and clustering of illness, the prevalence and
clustering of known risk factors, the discovery of new
risk factors and the effect of these diseases and risk fac-
tors on function and quality of life. The BHAS will add
new knowledge across a broad range of areas by:
1. Measuring current illness and risk factors in an older
general population sample. This will provide
contemporary prevalence estimates of common
diseases and symptoms in a community-dwelling
cohort as well as provide information on the
prevalence of under-researched conditions that
affect this age-group including hearing loss, spinal
pain, depression and cognitive impairment. Thecross-sectional and random recruitment design,
coupled with good response rates will maximize the
applicability of the results to the general baby-
boomer population.
2. Analysing the cumulative impacts of clustering of
illness and risk factors on function. In order to
improve the early stage diagnosis, treatment, and
prevention of chronic diseases associated with
ageing, it is imperative to gain an understanding of
the complex relationships among common diseases.
The wide range of both objective and subjective
measures collected will allow the identification of
novel associations and clustering of diseases within
individuals and determine their relative importance
in reduced function and quality of life.
3. Measuring a number of biomarkers and storing
serum, DNA and RNA for analysis of known and
potential new factors that put healthy ageing at risk.
The study will collect and conduct a wide range
haematological and biochemical tests and the bio-
banked samples will provide a resource to
investigate novel markers of ageing and disease
processes. The collection will act as a resource for
future genetic studies, since well-characterised
(well-phenotyped) populations are of immense value
for collaborative genetic population studies. The
collection of DNA and RNA will also allow genetic
and functional studies to examine pathological
pathways in disease processes associated with ageing.
4. Providing data for prioritised future health planning.
The collection of comprehensive population health
data (including environmental and genetic risk
factors) will contribute to the development of
strategies for facilitating healthy and productive
ageing in the general community.
5. Helping to define healthy ageing. Using a multi-
dimensional clustering approach, the study will
explore clusters of resilient individuals with low
illness and high physical and cognitive functioning.
It will provide important information about the
factors associated with optimal ageing. Thus, it will
meet the call for more refined outcome measures in
the definition of healthy ageing [62] but also inform
the understanding of the mechanisms and life-
course of resilience and frailty or disability.
In contrast to a number of large population surveys that
have been limited in the range of data that can be col-
lected for each subject, the BHAS aims to characterize in-
dividuals using questionnaire data, physical examination,
biomarkers and genetic markers with a view to longitu-
dinal follow-up, including incident illness, change in qual-
ity of life and function and health care utilisation. Given
the unique opportunity for extensive data linkage that
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longitudinal data will be related to hospital admissions
and (in future studies) mortality.
The results from the BHAS will provide a better under-
standing of the ageing process and a basis for planning fu-
ture health strategies for an ageing population. This will
be achieved by exploration of how combinations of co-
morbidities (and their risk factors) interact and impact on
function. The BHAS will provide health information on
the frequency with which co-morbidities cluster within in-
dividuals, which co-morbidities have the most effect on
function and how some co-morbidities modify (either
positively or negatively) the impact of others on function.
Previous studies that have reported the effects of combina-
tions of diseases have shown important modification ef-
fects of concurrent disease but have been retrospective,
examined a limited range of diseases and have been less
focused on specific age groups. The BHAS is specifically
designed to prospectively assess an extensive range of co-
existing morbidities and determine their effects on overall
function in an older population sample.
The BHAS will establish a framework that will enable the
development of interventions and health promotion pro-
grams that can be trialled, and their impact assessed quanti-
tatively, in a general population sample of ageing adults.
Finally, the BHAS provides feed-back to each partici-
pant on clinically relevant outcomes (see Tables 1 and 2)
with advice to take results to their usual medical practi-
tioner. This includes blood and other test results all of
which are scrutinised by a chief investigator. Where in-
dicated participants are contacted directly to inform
them of abnormal results requiring immediate attention.
Limitations of the study
The BHAS has a focus on studying the cumulative im-
pacts on function of linked or apparently disparate ill-
nesses within individuals at baseline and during ageing in
planned follow-up studies. Therefore the phenotyping
within individuals is time-consuming and labour intensive
and is confined to “baby boomers” at the onset of ageing.
This moderately-sized cohort will provide good power
cross-sectionally and longitudinally to study effects of
common risk factors and illnesses but the study is not
well-powered to examine associations for uncommon
events or risk factors and minor effect modification.
The population sample is drawn from the Busselton
Shire and is confined to a relatively narrow age-range, is
racially very homogeneous (<1% race other than Western
European) and all individuals currently live in a homoge-
neous climactic environment. Therefore generalisation to
other populations, ages and racial groups may have limita-
tions. However, pilot data from the first 300 subjects show
prevalence values for common risk factors such as obesity
and overweight to be almost identical to those in therecent nationally representative Australian Health Survey
(4364.0.55.003 - Australian Health Survey: Updated Re-
sults, 2011–2012).
The Busselton Shire has been the scene of repeated
cross-sectional health surveys since 1966 although there
have been only 2 major surveys since 1990 in 1994–95 and
2005–08. As such a number of participants in the BHAS
have participated in a previous survey or at least will be
aware of previous survey activity. As stated above, in the
current and also the previous major surveys, all partici-
pants are provided with results of clinically relevant tests
and where necessary are contacted by study investigators
with advice to attend their usual practitioner for appropri-
ate follow-up. These factors may also affect generalizability,
particularly with disease incidence and prevalence. An earl-
ier analysis of the impact of the surveys on mortality and
hospital morbidity found no conclusive impact of the
surveys [63].
Whilst these limitations to the generalisability of the
Busselton population to the whole Australia population
exist, they are more of a concern for generalization of ab-
solute risk and prevalence estimates and of less concern
for generalizability of relationship effect estimates which
are the primary focus of the study.
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